Use of Indipamide to reduce progression of disability in people with primary and secondary progressive multiple sclerosis (MS).
Key facts
- Where
- Amsterdam, HollandiaSee the site
- Phase
- 2. fázis
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Hollandia
- Amsterdam UMC StichtingAmsterdam, HollandiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Amsterdam UMC Stichting
- Trial code
- EU 2026-525260-18-00
- Record updated
- 2026. július 8.
- Original description
To demonstrate non-futility of indapamide treatment for the prevention of disability worsening in PPMS and SPMSRead full original descriptionShow less
Open-label, single-center, single-arm phase 2 futility trial evaluating the oral indapamide for reducing progression of disability in people with primary and secondary progressive multiple sclerosis (MS)
To demonstrate non-futility of indapamide treatment for the prevention of disability worsening in PPMS and SPMS
Inclusion: Written informed consent obtained; Aged between 18 and 65 years; Diagnosed with PPMS or SPMS, according to current diagnostic criteria; Screening Expanded Disability Status Scale score between 4.0 and 6.5 inclusive; Screening timed 25 foot walk (average of two trials) of 5 seconds or more for people with PPMS, or of 9 seconds or more for people with SPMS; Use of effective methods of contraception for women of childbearing potential.
Exclusion: Individuals who receive treatment with Botulinum toxin in the leg muscles during the trial; Individuals with recent gadolinium enhancement or new T2 lesions on brain/spinal cord MRI in the 6 months prior to inclusion; Concomitant use of corticosteroids; Individuals who use siponimod, ocrelizumab, natalizumab or other disease-modifying treatment for RRMS; Individuals with significant hepatic impairment (pre-existing or developing during the trial); Individuals with cardiac arrhythmia; Individuals with an allergy or other intolerability to indapamide; Individuals with renal insufficiency and an eGFR below 30ml/min per 1.73 m2; Individuals with a prolonged QT interval: individuals with frequency corrected QT (QTc) intervals of more than 450ms (men) or 470ms (women) at the screening examination will not be included in the study, and participants with QTc intervals of greater than 500ms on any of the other ECG examinations throughout the study will be excluded from the study; Individuals who start Baclofen or Tizanidine during the trial; Individuals who increase the dose of Baclofen or Tizanidine during the trial; Individuals with clinically significant abnormal screening labs; Individuals who are pregnant or currently breast-feeding; Individuals who use Fampridine or 4-aminopyridine; Individuals who start Fampridine or 4-aminopyridine during the trial.